Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.

Abstract

We report the safety and efficacy of autologous bone marrow transplantation (ABMT) in 30 patients with high-grade non-Hodgkin's lymphoma (NHL) in first complete remission (CR1) following remission induction chemotherapy. Two patients relapsed prior to ABMT. All patients were conditioned with high-dose melphalan. In Addition, ten received fractionated total body irradiation, one hemi-body irradiation and four high-dose etoposide. Unmanipulated non-cryopreserved autologous marrow was reinfused within 56 h of harvesting. Engraftment occurred in all patients with a median of 11 days of neutropenia (< 0.5 x 10(9) l-1), a median requirement for platelet transfusion of 3 days and packed red cell transfusion of 2 units, with a median hospital stay of 18 days post transplant. There was no procedure-related mortality and only minor morbidity was observed. Two patients relapsed at 1 and 2 months post transplantation, and one patient died of carcinoma of the lung 33 months after transplantation. The remaining 25 patients remain alive, well and in CR1 with a median follow-up of 44 months. The event-free survival at 3 years for all patients considered for ABMT was 83%. We conclude that ABMT for high-grade NHL in CR1 with non-cryopreserved marrow results in rapid haematological recovery without growth factor support. It is safe and is associated with high survival when used as consolidation of CR in high-risk patients.

• Authors: G H Jackson, A L Lennard, P R Taylor, P Carey, B Angus, H Lucraft, R G Evans, S J Proctor
• Journal: British journal of cancer (Br J Cancer) Vol. 70 Issue 3 Pg. 501-5 (Sep 1994) ISSN: 0007-0920 [Print] England
• PMID: 7521662 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Bleomycin
• Chlorambucil
• Vincristine
• Etoposide
• Doxorubicin
• Cyclophosphamide
• Prednisolone
• Vindesine
• Methylprednisolone
• Methotrexate

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bleomycin (administration & dosage)
• Blood Platelets (cytology, drug effects)
• Bone Marrow Transplantation
• Chlorambucil (administration & dosage)
• Combined Modality Therapy
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Etoposide (administration & dosage)
• Female
• Humans
• Lymphoma, Non-Hodgkin (therapy)
• Male
• Methotrexate (administration & dosage)
• Methylprednisolone (administration & dosage)
• Middle Aged
• Neutropenia (chemically induced, etiology, therapy)
• Neutrophils (cytology, drug effects)
• Platelet Count (drug effects)
• Prednisolone (administration & dosage)
• Retrospective Studies
• Risk Factors
• Vincristine (administration & dosage)
• Vindesine (administration & dosage)